When APS (Hughes syndrome) met the autoimmune/inflammatory syndrome induced by adjuvants (ASIA)

Lupus

Volumn 21, Issue 7, 2012, Pages 711-714

  Blank, M ^a   Israeli, E ^a   Shoenfeld, Y ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

adjuvant; ASIA; autoimmunity; Gulf war; macrophage myofacsciitis; silicone; vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; HEPATITIS B VACCINE; INFLUENZA VACCINE; PHARMACEUTICAL VEHICLES AND ADDITIVES; PHOSPHOLIPID ANTIBODY; PHOSPHORYL LIPID A; TETANUS TOXOID;

ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; AUTOIMMUNE SYNDROME INDUCED BY ADJUVANTS; CLINICAL FEATURE; CONFERENCE PAPER; EMULSION; HUMAN; PRIORITY JOURNAL; VACCINATION REACTION;

ADJUVANTS, IMMUNOLOGIC; ANTIPHOSPHOLIPID SYNDROME; HEPATITIS B VACCINES; HUMANS; INFLUENZA VACCINES; TETANUS TOXOID;

EID: 84861538326     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203312438115     Document Type: Conference Paper

References (30)

1. Shoenfeld Y, Aron-Maor A. Vaccination and autoimmunity-'vaccinosis': a dangerous liaison?. J Autoimmun. 2000 ; 14: 1-10
2. Salemi S, D'Amelio R. Could autoimmunity be induced by vaccination?. Int Rev Immunol. 2010 ; 29: 247-269
3. Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y. Infections and autoimmunity-friends or foes?. Trends Immunol. 2009 ; 30: 409-414
4. Guilherme L, Kalil J. Rheumatic fever and rheumatic heart disease: cellular mechanisms leading autoimmune reactivity and disease. J Clin Immunol 2010; 30: 17-23.
5. Shoenfeld Y, Agmon-Levin N. 'ASIA'-autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011 ; 36: 4-8
6. Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Adjuvants and autoimmunity. Lupus. 2009 ; 18: 1217-1225
7. Israeli E, Pardo A. The sick building syndrome as a part of the autoimmune (auto-inflammatory) syndrome induced by adjuvants. Mod Rheumatol. 2011 ; 21: 235-239
8. Hughes GRV, Harris EN and Gharavi AE. Anti-phospholipid antibodies. Clin Rheum Dis 1985; 11: 591-609.
9. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002 ; 46: 1019-1027
10. Shoenfeld Y. Systemic antiphospholipid syndrome. Lupus. 2003 ; 12: 497-498
11. Blank M, Krause I, Fridkin M, et al. Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest. 2002 ; 109: 797-804
12. Blank M, Asherson RA, Cervera R, Shoenfeld Y. Antiphospholipid syndrome infectious origin. J Clin Immunol. 2004 ; 24: 12-23
13. Gharavi AE, Pierangeli SS, Harris EN. Viral origin of antiphospholipid antibodies: endothelial cell activation and thrombus enhancement by CMV peptide-induced APL antibodies. Immunobiology. 2003 ; 207: 37-42
14. Zivkovic I, Stojanovic M, Petrusic V, Inic-Kanada A, Dimitrijevic L. Induction of APS after TTd hyper-immunization has a different outcome in BALB/c and C57BL/6 mice. Am J Reprod Immunol 201; 65: 492-502.
15. Zivkovic I, Petrusic V, Stojanovic M et al. Induction of decreased fecundity by tetanus toxoid hyper-immunization in C57BL/6 mice depends on the applied adjuvant. Innate Immun. Epub ahead of print Sept 16 2011.
16. Diphtheria-tetanus vaccine: first report of antiphospholipid syndrome: case report. Reactions Weekly 2011; 20: 0114-9954.
17. Huh JY, Yi DY, Hwang SG, Choi JJ, Kang MS. Characterization of antiphospholipid antibodies in chronic hepatitis B infection. Korean J Hematol. 2011 ; 46: 36-40
18. Zachou K, Liaskos C, Christodoulou DK, et al. Anti-cardiolipin antibodies in patients with chronic viral hepatitis are independent of beta2-glycoprotein I cofactor or features of antiphospholipid syndrome. Eur J Clin Invest. 2003 ; 33: 161-168
19. Martinuc Porobic J, Avcin T, Bozic B, et al. Anti-phospholipid antibodies following vaccination with recombinant hepatitis B vaccine. Clin Exp Immunol. 2005 ; 142: 377-380
20. Mehdi H, Naqvi A, Kamboh MI. Recombinant hepatitis B surface antigen and anionic phospholipids share a binding region in the fifth domain of beta2-glycoprotein I (apolipoprotein H). Biochim Biophys Acta. 2008 ;: 1782 163-168
21. Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barre syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med. 1998 ; 339: 1797-1802
22. Toplak N, Kveder T, Trampus-Bakija A, et al. Autoimmune response following annual influenza vaccination in 92 apparently healthy adults. Autoimmun Rev. 2008 ; 8: 134-138
23. Tarjan P, Sipka S, Lakos G, Kiss E, Ujj G, Szegedi G. Influenza vaccination and the production of anti-phospholipid antibodies in patients with systemic lupus erythematosus. Scand J Rheumatol. 2006 ; 35: 241-249
24. Mbow ML, De Gregorio E, Valiante NM, Rappuoli R. New adjuvants for human vaccines. Curr Opin Immunol. 2010 ; 22: 411-416
25. Hornung V, Bauernfeind F, Halle A, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008 ; 9: 847-856
26. Kool M, Soullié T, van Nimwegen M, et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med. 2008 ; 205: 869-882
27. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol. 2008 ; 8: 279-289
28. Marichal T, Ohata K, Bedoret D, et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med. 2011 ; 17: 996-1002
29. Takeshita F, Ishii KJ. Intracellular DNA sensors in immunity. Curr Opin Immunol. 2008 ; 20: 383-388
30. Schneider-Ohrum K, Giles BM, Weirback HK, et al. Adjuvants that stimulate TLR3 or NLPR3 pathways enhance the efficiency of influenza virus-like particle vaccines in aged mice. Vaccine. 2011 ; 29: 9081-9092